Conclusions

While dermatologists continue to show a need for education on immune escape mechanisms and the latest immunotherapy data, both oncologists and dermatologists need more education on identifying BCC and cSCC patients who would benefit from immunotherapy. Future education should focus on individual patient scenarios.

In 2021, analyzing the dispensed prescription and medical claims data from learners pre- and post- education will offer insight into how/if HCPs are applying the latest clinical trial data in practice.

Next Steps: Claims Analysis

FC21 Poster: Med Learning Group, CME supported by educational grants from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Next Steps: Claims Analysis

Will report on the incremental use of specific therapeutic classes pre- and post- 2021 educational initiatives in cSCC and BCC

Has access to 600+ million de-identified patient records.

Analyzes dispensed prescription as well as medical claims data from learners from Med Learning Group programming as well as control groups to assess behavior change over the course of the education.

Provides for concrete reporting regarding how/if HCPs are applying the latest clinical trial data in practice.

Presented: Full Clinical Dermatology Conference October 21 - 24, 2021

Over Time, Learners Have Shown Progress in Applying Tumor Staging and Risk Evaluation to Stratify cSCC Candidates; Room for Growth Across Audiences

While Gaps Remain, Learners Also Have Shown Progress in Applying Immunotherapy Clinical Data to cSCC Treatment Choice

Dermatologists’ Ability to Apply the Latest Clinical Trial Data on Immunotherapy to BCC Patient Scenarios Increased With Time

Whiteboard/3D/360° Animations Were Shared with Patients

2,858 downloads

71% reported sharing with patients (N=461)